Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) P/E Ratio History
ExpensiveTrading at 57.3x vs 5Y avg 10.4x · 100th percentile · Material premium to history · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) trades at a price-to-earnings ratio of 57.3x, with a stock price of $10.89 and trailing twelve-month earnings per share of $0.29.
The current P/E is 451% above its 5-year average of 10.4x. Over the past five years, DMAA's P/E has ranged from a low of 0.2x to a high of 51.2x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Financial Services sector median P/E of 12.1x, DMAA trades at a 376% premium to its sector peers. The sector includes 763 companies with P/E ratios ranging from 0.0x to 190.1x.
Relative to the broader market, DMAA commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DMAA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DMAA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
DMAA P/E vs Peers
Healthcare SPACs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $362B | 148.2 | 6.98 | +8% | |
| $168B | 41.9 | - | -4% | |
| $515B | 49.9 | - | -1% | |
| $127B | 13.8Lowest | - | +178%Best | |
| $1.3T | 43.9 | 1.52Best | +96% | |
| $248B | 26.8 | 9.10 | +88% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
DMAA Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $10.48 | $0.20 | 51.2x | +392% |
| FY2025 Q4 | Dec 31 2025 | $10.37 | $49.32 | 0.2x | -98% |
| FY2025 Q3 | - | $10.27 | $49.29 | 0.2x | -98% |
| FY2025 Q2 | Jun 30 2025 | $10.20 | $49.21 | 0.2x | -98% |
| FY2025 Q1 | Mar 31 2025 | $10.02 | $49.14 | 0.2x | -98% |
Average P/E for displayed period: 10.4x
DMAA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DMAA — Frequently Asked Questions
Quick answers to the most common questions about buying DMAA stock.
What is DMAA's P/E ratio?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) trailing twelve-month P/E ratio is 57.3x, based on TTM diluted EPS of $0.29. The 5-year average P/E is 10.4x and the historical range spans 0.2x to 51.2x.
Is DMAA stock overvalued or undervalued?
DMAA trades at 57.3x P/E, above its 5-year average of 10.4x. The 100th percentile ranking within the 0.2x–51.2x historical range indicates a premium to historical valuation.
Is DMAA stock expensive?
Yes, DMAA is expensive relative to its own history. The current P/E of 57.3x is above the 5-year average of 10.4x and also above the Financial Services sector median of 12.1x. The stock sits at the 100th percentile of its 5-year valuation range.
What is DMAA's historical P/E range?
Over the past 5 years, DMAA's P/E ratio has ranged from 0.2x to 51.2x, with a median of 0.2x and an average of 10.4x. The current P/E of 57.3x places the stock at the 100th percentile of this range. Full historical data spans 2025–2026.
How does DMAA's P/E compare to the S&P 500?
DMAA trades at 57.3x P/E versus the S&P 500 median of 21.8x. The 163% premium to the market typically reflects higher expected earnings growth or quality.
How does DMAA's valuation compare to Financial Services peers?
Drugs Made In America Acquisition Corp. Ordinary Shares P/E of 57.3x compares to the Financial Services sector median of 12.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is DMAA's PEG ratio?
DMAA PEG ratio is N/A, based on a P/E of 57.3x and EPS growth of 439.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is DMAA's earnings yield?
DMAA earnings yield is 1.74%, the inverse of its 57.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.